+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Opioid Related Disorder - Pipeline Insight, 2021

  • ID: 5237648
  • Clinical Trials
  • September 2021
  • Region: Global
  • 80 Pages
  • DelveInsight

FEATURED COMPANIES

  • ADial Pharmaceuticals
  • Astellas Pharma
  • BioCorRx
  • DemeRx
  • MediciNova
  • Opiant Pharmaceuticals
This “Opioid Related Disorder - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Opioid Related Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Opioid Related Disorder Understanding

Opioid Related Disorder: Overview


Opioids are a class of drugs that bind with the opioid receptor present on the central nervous system in the brain and body to reduce the sensation of pain. Opioids predominantly include prescription pain relievers, synthetic opioids, and heroines. Symptoms can include nausea, vomiting, weakened immune system, clogged blood vessels, and hallucinations. Opioid Related Disorder is diagnosed by clinicians by taking history, evaluating symptoms, using clinical information to identify a problematic pattern of opioid related impairment and distress as well as using 11 diagnostic criteria mentioned in Diagnostic and Statistical Manual of Mental Disorders, fifth edition. An effective treatment for Opioid Related Disorder generally includes pharmacotherapy. Three FDA approved medications present for the treatment of individuals with Opioid Related Disorder are naltrexone, methadone, and buprenorphine.

"Opioid Related Disorder - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Related Disorder pipeline landscape is provided which includes the disease overview and Opioid Related Disorder treatment guidelines. The assessment part of the report embraces, in depth Opioid Related Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Related Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Related Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Related Disorder.

Opioid Related Disorder Emerging Drugs Chapters


This segment of the Opioid Related Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Opioid Related Disorder Emerging Drugs


OPNT003: Opiant Pharmaceuticals


OPNT003 is a nasal nalmefene and is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. The development of OPNT003 is supported by grants from the NIH and the BARDA. The Company plans to file a 505(b)(2) New Drug Application for OPNT003 with the U.S. Food and Drug Administration by the end of 2021.

ASP8062: Astellas Pharma


ASP8062 is an orally active γ-amino-butyric acid type B (GABA B) receptor positive allosteric modulator. The drug is in Phase II clinical studies for the treatment of opioid related disorder. In July 2020, Astellas Pharma announced it had been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) in the US to help fund two Phase I clinical studies to evaluate the safety and efficacy of ASP8062 as an add-on maintenance therapy for opioid use disorder.

Opioid Related Disorder: Therapeutic Assessment


This segment of the report provides insights about the different Opioid Related Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Opioid Related Disorder


There are approx. 40+ key companies which are developing the therapies for Opioid Related Disorder. The companies which have their Opioid Related Disorder drug candidates in the most advanced stage, i.e. Phase III include, Opiant Pharmaceuticals.

Phases


This report covers around 40+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Opioid Related Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Opioid Related Disorder: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Opioid Related Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Related Disorder drugs.

Opioid Related Disorder Report Insights

  • Opioid Related Disorder Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Opioid Related Disorder Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Opioid Related Disorder drugs?
  • How many Opioid Related Disorder drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid Related Disorder?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Opioid Related Disorder therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Opioid Related Disorder and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Astellas Pharma
  • Opiant Pharmaceuticals
  • Nasus Pharma
  • GW Pharmaceuticals
  • Benuvia Therapeutics
  • MediciNova
  • DemeRx
  • BioXcel Therapeutics
  • ADial Pharmaceuticals
  • Orexo
  • Alar Pharmaceuticals
  • BioCorRx
  • Revive Therapeutics
  • Vivera Pharmaceuticals

Key Products

  • ASP8062
  • OPNT003
  • NS-001
  • Cannabidiol
  • Buprenorphine/naloxone sublingual
  • Ibudilast
  • DMX-1002
  • AD-04
  • Dexmedetomidine
  • OX-124
  • ALA-1000
  • BICX-104
  • Psilocybin
  • Cannabidiol


This product will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ADial Pharmaceuticals
  • Astellas Pharma
  • BioCorRx
  • DemeRx
  • MediciNova
  • Opiant Pharmaceuticals

IntroductionExecutive Summary
Opioid Related Disorder: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Opioid Related Disorder - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis

OPNT003: Opiant Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

ASP8062: Astellas Pharma
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I/II)
  • Comparative Analysis

DMX-1002: DemeRx
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical/Discovery Stage Products
  • Comparative Analysis

Psilocybin: Revive Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Opioid Related Disorder Key CompaniesOpioid Related Disorder Key ProductsOpioid Related Disorder- Unmet NeedsOpioid Related Disorder- Market Drivers and BarriersOpioid Related Disorder- Future Perspectives and ConclusionOpioid Related Disorder Analyst ViewsAppendix
List of Tables
Table 1 Total Products for Opioid Related Disorder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Opioid Related Disorder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Astellas Pharma
  • Opiant Pharmaceuticals
  • Nasus Pharma
  • GW Pharmaceuticals
  • Benuvia Therapeutics
  • MediciNova
  • DemeRx
  • BioXcel Therapeutics
  • ADial Pharmaceuticals
  • Orexo
  • Alar Pharmaceuticals
  • BioCorRx
  • Revive Therapeutics
  • Vivera Pharmaceuticals
Note: Product cover images may vary from those shown